Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The evolving role of cytokines for CAR-T cell manufacturing and beyond.

Nature biomedical engineering·2026
Same author

TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

Leukemia·2026
Same author

NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors.

Nature communications·2026
Same author

FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

Blood advances·2026
Same author

Ablation of prostaglandin E<sub>2</sub> signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours.

Nature biomedical engineering·2026
Same author

RIG-I agonists promote antigen-spreading and facilitate durable CAR-T responses in pancreatic ductal adenocarcinoma.

Journal for immunotherapy of cancer·2026

相关实验视频

Updated: Jun 16, 2025

A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.3K

在固体和血液癌症中RORing CAR T 细胞:相同但不同

Sebastian Kobold1,2,3

  • 1Division of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.

Clinical cancer research : an official journal of the American Association for Cancer Research
|December 3, 2024
PubMed
概括

一项I期临床研究发现,抗ROR1仿真抗原受体 (CAR) T细胞对某些癌症患者是安全的. CAR T细胞疗法在慢性淋巴细胞白血病中表现出活性,但在非小细胞肺癌和三阴性乳腺癌中有效性有限.

更多相关视频

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.9K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K

相关实验视频

Last Updated: Jun 16, 2025

A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.3K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.9K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 细胞疗法细胞疗法

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法是癌症治疗的一个有前途的方法.
  • ROR1是一种向抗原,表达在各种癌细胞上,包括白血病和固体瘤.

研究的目的:

  • 在I期临床试验中评估抗ROR1CART细胞的安全性和初步疗效.
  • 在患有慢性淋巴细胞白血病,非小细胞肺癌和三阴性乳腺癌的患者中评估抗ROR1CAR T细胞的活性.

主要方法:

  • 第一阶段临床试验设计.
  • 向患者提供抗ROR1的CAR T细胞.
  • 安全性,耐受性和初步抗瘤活性的评估.

主要成果:

  • 抗ROR1 CAR T细胞产品安全地给患者使用.
  • 该疗法在慢性淋巴细胞白血病患者中表现出活性.
  • 在患有非小细胞肺癌和三阴性乳腺癌的患者中观察到有限的活性.

结论:

  • 抗ROR1CAR T细胞疗法是安全的,并且在慢性淋巴细胞白血病中显示出潜力.
  • 需要进一步研究以优化非小细胞肺癌和三阴性乳腺癌的疗效.